To hear about similar clinical trials, please enter your email below
Trial Title:
Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection
NCT ID:
NCT06006845
Condition:
Tumor
COVID-19
Conditions: Official terms:
COVID-19
Conditions: Keywords:
Tumor patients
COVID-19
antitumor therapy
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Retrospective
Summary:
The goal of this observational study is to study the safety of initiation of antitumor
therapy early after nucleic acid test turn negativity in tumor patients infected with
COVID-19. The main questions aims to answer are:
- Whether initiation of antitumor therapy early after nucleic acid test turn
negativity in tumor patients infected with COVID-19 increases adverse events related
to antitumor therapy.
- Whether initiation of antitumor therapy early after nucleic acid test turn
negativity in tumor patients infected with COVID-19 increases risk of re-infection
of COVID-19.
- How initiation of antitumor therapy early after nucleic acid test turn negativity in
tumor patients infected with COVID-19 affects QoL of tumor patients
Participants will be asked to answer the question about:
- the severity and duration of COVID-19 symptoms
- the date of diagnosis of COVID-19
- the date of negative nucleic acid test
- the QoL of life before infection with COVID-19, during infection of COVID-19, after
nucleic acid test negativity and receiving antitumor therapy
Criteria for eligibility:
Study pop:
Tumor patients infected with COVID-19 from December 1, 2022 to May 31, and received
systemic antitumor therapy after infected with COVID-19.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Tumor patients diagnosed with COVID-19 infection at our center from December 1, 2022
to May 31.
- COVID-19 was confirmed by antigen testing or nucleic acid testing.
- Tumor was confirmed by pathology.
- Patients received systemic antitumor therapy after infected with COVID-19.
Exclusion Criteria:
- COVID-19 was not confirmed by antigen testing or nucleic acid testing
- Tumor was not confirmed by pathology
- Patients did not receive systemic antitumor therapy
- Patients died before receiving systemic antitumor therapy
Gender:
All
Minimum age:
18 Years
Maximum age:
85 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Seventh Affiliated Hospital, Sun Yat-sen University
Address:
City:
Shenzhen
Zip:
518107
Country:
China
Status:
Recruiting
Contact:
Last name:
Xiaofen Pan, MD
Phone:
+8618124671750
Email:
panxf8@mail.sysu.edu.cn
Contact backup:
Last name:
Bo Wang, MD
Phone:
0755-81206796
Email:
wangb68377@sina.com
Start date:
December 1, 2022
Completion date:
August 31, 2024
Lead sponsor:
Agency:
The Seventh Affiliated Hospital of Sun Yat-sen University
Agency class:
Other
Source:
The Seventh Affiliated Hospital of Sun Yat-sen University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06006845
